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Abstract
The human immunodeficiency virus (HIV) protease inhibitor saquinavir shows anticancer activity. Although its nitric
oxide–modified derivative saquinavir-NO (saq-NO) was less toxic to normal cells, it exerted stronger inhibition of B16
melanoma growth in syngeneic C57BL/6 mice than saquinavir did. Saq-NO has been shown to block proliferation, up-
regulate p53 expression, andpromote differentiation of C6 glioma andB16 cells. The anticancer activity of substances is
frequently hampered by cancer cell chemoresistancemechanisms. Therefore,we here investigated the roles of p53 and
the ATP-binding cassette (ABC) transporters P-glycoprotein (P-gp), multidrug resistance–associated protein 1 (MRP1),
and breast cancer resistance protein 1 (BCRP1) in cancer cell sensitivity to saq-NO to get more information about the
potential of saq-NO as anticancer drug. Saq-NO exerted anticancer effects in lower concentrations than saquinavir in a
panel of human cancer cell lines. Neither p53 mutation or depletion nor expression of P-gp, MRP1, or BCRP1 affected
anticancer activity of saq-NO or saquinavir. Moreover, saq-NO sensitized P-gp–, MRP1-, or BCRP1-expressing cancer
cells to chemotherapy. Saq-NO induced enhanced sensitization of P-gp– or MRP1-expressing cancer cells to chemo-
therapy compared with saquinavir, whereas both substances similarly sensitized BCRP1-expressing cells. Washout
kinetics and ABC transporter ATPase activities demonstrated that saq-NO is a substrate of P-gp as well as of MRP1.
These data support the further investigation of saq-NO as an anticancer drug, especially in multidrug-resistant tumors.
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Introduction
Anti–human immunodeficiency virus (HIV) drugs have been consid-
ered as potential anticancer drugs since the early 1990s [1]. The HIV
protease inhibitors were developed in the early 1990s and were sub-
sequently included in highly active antiretroviral therapy treatment
regimens. The idea that HIV protease inhibitors may also exert direct
anticancer effects stems from the observation that successful treat-
ment of HIV-related Kaposi sarcoma by highly active antiretroviral
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therapy was not always directly connected with immune reconstitu-
tion [2,3]. In the meantime, different antitumor mechanisms have
been described for HIV protease inhibitors [1].
Saquinavir was the first US Food and Drug Administration–
approved HIV protease inhibitor [1]. The substance exerts non–
immune-mediated anticancer activity by mechanisms including
inhibition of angiogenesis through inhibition of proteolysis of matrix
metalloprotease 2, inhibition of proteasome activity, inhibition of
nuclear factor κB, and inhibition of Akt phosphorylation [4–9]. In
cells from different cancer entities, saquinavir induced apoptosis in a
concentration-dependent manner and increased the radiosensitivity
of prostate cancer cells [5]. Moreover, saquinavir was more effective
in imatinib-resistant chronic myelogenous leukemia cell line than in
an imatinib-sensitive one and in sensitized imatinib-resistant myelog-
enous leukemia cells to imatinib [10].
ATP-binding cassette (ABC) transporters are ATP-dependent pumps
that transport substances across biologic membranes. They play im-
portant roles in general in the passage of drugs through cellular and
tissue barriers and in cancer cell chemoresistance phenotypes [11–14].
Saquinavir has been described to be a substrate of P-glycoprotein (P-gp,
also called multidrug resistance gene 1 [MDR1], the gene product of
ABCB1), and the multidrug resistance proteins 1 and 2 (MRP1 and
MRP2) [15–19]. Moreover, saquinavir was shown to be an inhibitor of
the breast cancer resistance protein (BCRP1, gene product of ABCG2)
but not a substrate [20,21].
Recently, a nitric oxide–modified derivative, saquinavir-NO (saq-NO),
was synthesized and investigated for anticancer activity [22]. In con-
trast to saquinavir, saq-NO had no effect on the viability of primary
cells, and it drastically reduced B16 mouse melanoma growth in syn-
geneic C57BL/6 mice. At the equivalent of the 100% lethal dose of
saquinavir, saq-NO treatment caused no apparent signs of toxicity.
Saq-NO blocked the proliferation of C6 rat glioma and B16 cells,
upregulated p53 expression, and promoted the differentiation of these
two cell types into oligodendrocytes or Schwann-like cells, respectively.
Although saquinavir has been supposed to decrease tumor cell viabil-
ity by inhibiting Akt, saq-NO did not exert its anticancer effects by
inhibition of the phosphatidylinositol 3-kinase/Akt signaling path-
way [22].
To gain further insights in the antitumoral potential of saq-NO,
we compared the efficacies of saquinavir and saq-NO in the context
of prominent cancer cell chemoresistance mechanisms. The effects of
saquinavir or saq-NO were studied in cell lines expressing the ABC
transporters P-gp, MRP1, or BCRP1. Moreover, the influence of
both substances on ABC transporter–mediated cellular drug efflux
was examined. In addition, Saq-NO was suggested to act (in part)
through activation of p53 [22]. P53 is known to be frequently in-
activated in cancer cells, and loss of p53 function contributes to
cancer cell chemoresistance [23]. Therefore, we also compared anti-
cancer effects of saquinavir and saq-NO in cancer cells in dependence
of p53 function.
Materials and Methods
Cell Lines
The neuroblastoma cell line UKF-NB-3 as well as the UKF-NB-3
subline adapted to 10 ng/ml vincristine (UKF-NB-3rVCR10) were es-
tablished as described before [24]. The alveolar rhabdomyosarcoma
cell line Rh30 was kindly provided by Dr P.J. Houghton (St Jude’s
Children’s Research Hospital, Memphis, TN). The vincristine-resistant
rhabdomyosarcoma cell line Rh30rVCR10 was established by adapta-
tion of Rh30 cells to growth in the presence of vincristine 10 ng/ml
[25]. P53-negative and P-gp–negative PC-3 prostate cancer cells ex-
pressing low MRP1 levels were received from ATCC (Manassas, VA).
The vincristine-resistant subline PC-3rVCR20 was established by
adaptation of PC-3 to growth in the presence of vincristine 20 ng/ml
resulting in a cell line showing high MRP1 overexpression but no
P-gp expression [25].
P53 status, P-gp expression, MRP1 expression, and BCRP1 expres-
sion of the investigated cell lines are shown in Table 1 [24–26] (own
unpublished data). All cell lines were propagated in Iscove’s modified
Dulbecco medium supplemented with 10% FBS, 100 IU/ml penicil-
lin, and 100 mg/ml streptomycin at 37°C.
Viral Transduction
Standard molecular cloning techniques were used to generate lenti-
viral vectors based on Lentiviral Gene Ontology (LeGO) vector tech-
nology [27] (www.lentigo-vectors.de). To suppress expression of p53,
short hairpin RNA (shRNA) against p53 was used (at least 70% down-
regulation; Figure W1). For overexpression of ABC transporters, com-
plementary DNA (cDNA) coding for P-gp (approximately 50-fold
increased expression; Figure W2) and for BCRP1 (approximately
400-fold increased expression; Figure W3) was used.
Drugs
Vincristine, verapamil, NEM (N -ethylmaleimide), and GS (re-
duced glutathione) were obtained from Sigma-Aldrich (Deisenhofen,
Germany). Rhodamine 123 (R123) was purchased from Merck Bio-
sciences (Darmstadt, Germany). Saquinavir was obtained from Roche
(Grenzach-Wyhlen, Germany). Mitoxantron was received from GRY
Pharma (Kirchzarten, Germany). MK571 and 5-carboxyfluorescein
diacetate (5-CFDA) were obtained from Calbiochem (through Merck
KGaA, Darmstadt, Germany). Saq-NO and WK-X-34 were synthe-
sized as described before [22,28].
Viability Assay
Cell viability was tested by the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazoliumbromide (MTT) dye reduction assay after 96 hours
of incubation, modified as described before [29]. All experiments
were performed at least in triplicate.
Flow Cytometry and Investigation of Efflux of ABC
Transporter Substrates
Antibodies directed against P-gp (Alexis Biochemicals through
AXXORA Deutschland, Lörrach, Germany), MRP1, and breast can-
cer resistance protein (BCRP1/ABCG2; both Kamiya Biomedical
Company, Seattle, WA) followed by secondary antibody labeled with
phycoerythrin (PE; R&D, Wiesbaden, Germany) were used to detect
protein expression by flow cytometry (FACSCalibur; BD Biosciences,
Heidelberg, Germany).
To investigate P-gp–mediated substance efflux, cells were pre-
incubated with different concentrations of saquinavir and saq-NO
for 30 minutes. Verapamil 10 μM was used as a positive control for
P-gp–mediated efflux. R123 1 μMwas added for another 30 minutes.
Then, the cell culture medium was removed, cells were washed three
times with PBS, and fresh medium containing verapamil, saquinavir,
or saq-NO was added. After another 45 minutes, cellular fluorescence
was analyzed by flow cytometry (FACSCalibur). R123 was detected at
the FL1 channel.
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To investigate MRP1-mediated efflux, the same protocol as for
P-gp–mediated efflux was carried out with MRP1-expressing cell line
PC-3rVCR20, using the MRP1-substrate 5-CFDA and the MRP1
inhibitor MK571 as a positive control. 5-CFDA was detected at the
FL1 channel.
For washout kinetic experiments, cells were incubated for 1 hour
with 1 μMR123 (P-gp substrate) or with 4 μM5-CFDA (MRP1 sub-
strate), respectively. Saquinavir 20 μM, saq-NO 20 μM, verapamil
10 μM (positive control for P-gp), or MK571 10 μM (positive control
for MRP1) was added immediately. Cells were resuspended in sup-
plemented medium, and cellular fluorescence was measured after
different time points (t0, t5, t15, t30, t60, and t120 minutes) by flow
cytometry (FACSCalibur).
To determine IC50 values for P-gp–mediated drug efflux, P-gp–
expressing cells were incubated for 1 hour with 1 μM R123. Then,
cell culture medium was removed, cells were washed three times with
PBS, fresh medium (with or without saquinavir or saq-NO) was
added, and cellular fluorescence was measured immediately (t0) and
after 15 minutes (t15). Then, t15 was subtracted from t0. R123 efflux
(t0 − t15) in the absence of drugs was defined as 100% efflux. The R123
efflux (t0 − t15) in the presence of saquinavir or saq-NO was expressed
in percent relative to R123 efflux (t0 − t15) in the absence of drugs. The
concentrations that inhibit 50% of P-gp–mediated drug efflux were
calculated and expressed as IC50 values.
All experiments were performed at least in triplicate.
Determination of ATPase Activity
The P-gp–ATPase activity and the MRP1-ATPase activity were
determined using membrane preparations (Pgp-Membran: BD Bio
sciences; MRP1-membrane: Solvo Biotechnology, Budapest, Hungary)
and an established kit (BD Biosciences) following the manufacturer’s
instruction. All experiments were performed at least in triplicate.
Western Blot
Cells were lysed in Triton X sample buffer and separated by SDS-
PAGE, as described before [30]. Proteins were detected using specific
antibodies against β-actin (Sigma, Munich, Germany) or p53 (Alexis
Biochemicals through AXXORADeutschland) and were visualized by
enhanced chemiluminescence using a commercially available kit
(Amersham through GE Healthcare, Munich, Germany). All experi-
ments were performed at least in triplicate.
Fluorescence Microscopy
Pictures were takenwith an IX71 fluorescencemicroscope (Olympus,
Hamburg, Germany). Ceruleanwas detected at 433/475 nm (excitation/
emission), enhanced green fluorescent protein was detected at
484/507 nm (excitation/emission), and mCherry was detected at
587/610 nm (excitation/emission).
Statistical Analysis
Two groups were compared by t-test. More groups were compared
by ANOVA with subsequent Student-Newman-Keuls test.
Results
Influence of Saquinavir and Saq-NO on Cancer Cell Viability
Saq-NO caused a stronger decrease in cancer cell viability than
saquinavir in all investigated cell lines (Table 1). P-gp expression,
BCRP1 expression, or p53 status (wild-type, mutated, loss of ex-
pression) did not significantly influence cancer cell sensitivity to
both substances.
To further investigate the role of p53 and p53 wild-type cell line
UKF-NB-3 was transduced with LeGO vectors [27] containing shRNA
against p53 to suppress p53 expression (UKF-NB-3p53-shRNA; Fig-
ure W1). UKF-NB-3p53-shRNA cells and the cell line resulting from
transduction of UKF-NB-3 with control (scrambled) shRNA (UKF-
NB-3scr-shRNA; Figure W1) showed no differences in IC50 values for
saquinavir and saq-NO, when compared with UKF-NB-3 (Table 1).
Therefore, the saquinavir- and saq-NO–induced decreases in cancer cell
viability do not depend on p53 activity.
Influence of Saquinavir and Saq-NO on P-gp Function
Saquinavir was already shown to interfere with the P-gp–mediated
drug efflux [15,16,19]. Here, we compared the effects of saquinavir
Table 1. Cellular p53 Status, P-gp Expression, MRP1 Expression, BCRP1 Expression, and Tumor Cell Sensitivity to Saquinavir and Saq-NO.
Cell Line p53 Status* P-gp† MRP1‡ BCRP1§ Saquinavir IC50 (μM) Saq-NO IC50 (μM)
UKF-NB-3 WT − − − 23.2 ± 6.7 9.40 ± 2.0¶
UKF-NB-3rVCR10 mut (C135F) + − − 18.9 ± 4.5 6.6 ± 1.5¶
UKF-NB-3MDR1 WT + − − 27.8 ± 5.3 13.5 ± 2.3¶
UKF-NB-3LeGO-Cer2# WT − − − 21.0 ± 1.4 10.3 ± 2.4¶
UKF-NB-3BCRP1 WT − − + 27.5 ± 5.0 11.5 ± 1.2¶
UKF-NB-3LeGO-iG2** WT − − − 20.4 ± 3.6 10.1 ± 0.9¶
UKF-NB-3p53-shRNA depl. − − − 20.2 ± 4.3 9.7 ± 1.3¶
UKF-NB-3scr-shRNA†† WT − − − 21.3 ± 2.1 9.3 ± 1.7¶
Rh30 mut (R273C) − − − 18.7 ± 3.0 8.4 ± 3.8¶
Rh30rVCR10 mut (R273C) + − − 26.7 ± 3.5 12.7 ± 1.9¶
PC-3 del. − − − 14.3 ± 2.0 5.6 ± 0.7¶
PC-3rVCR20 del. − + − 16.1 ± 1.9 7.5 ± 0.8¶
Values are mean ± SD from three independent experiments.
*p53 status: WT = wild-type p53, mut = mutated p53, depl. = shRNA-induced p53 depletion, del. = deleted.
†P-gp expression: + = overexpression, − = no overexpression.
‡MRP1 expression: + = overexpression, − = no overexpression.
§BCRP1 expression: + = overexpression, − = no overexpression.
¶P < .05 relative to saquinavir.
#Control vector for MDR1 expressing only Cerulean.
**Control vector for BCRP1 expressing only eGFP.
††Control vector for p53-shRNA expressing scrambled shRNA.
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and saq-NO on P-gp. First, the influence of both drugs was investi-
gated on sensitivity of the P-gp–expressing cell lines to the structurally
different P-gp substrates vincristine, actinomycin D, and paclitaxel
(Table 2). Nontoxic saq-NO concentrations caused stronger (4- to
80-fold) sensitization of UKF-NB-3rVCR10 cells and Rh30rVCR10
cells to all three chemotherapeutic drugs than saquinavir. The effects
of vincristine, actinomycin D, or paclitaxel on the parental cell lines
UKF-NB-3 and Rh30 that do not express P-gp were not affected by
nontoxic concentrations of saquinavir or saq-NO.
To further investigate the influence of saquinavir and saq-NO on
P-gp (MDR1), UKF-NB-3 cells were transduced with LeGO vectors
[27] containing cDNA coding for MDR1 to induce overexpression of
P-gp (UKF-NB-3MDR1; Figure W2). UKF-NB-3MDR1 cells and the
cell line resulting from transduction of UKF-NB-3 with empty con-
trol vector LeGO-Cer2 (UKF-NB-3LeGO-Cer2; Figure W2) displayed
similar sensitivity to saquinavir and saq-NO as UKF-NB-3 (Table 1).
Effects of different saquinavir and saq-NO concentrations were
investigated for their influence on vincristine sensitivity of UKF-
NB-3MDR1 cells (Table 3). Saquinavir and saq-NO both sensitized
UKF-NB-3MDR1 cells to vincristine in a concentration-dependent
manner, whereas saq-NO again exerted considerably stronger effects
(up to 30-fold).
R123 (rhodamine 123) is a fluorescent dye that is transported by
P-gp. Flow cytometry analysis indicated that saquinavir and saq-NO
increased R123 fluorescence in UKF-NB-3rVCR10 and UKF-NB-
3MDR1 cells (Figure 1A) with saq-NO showing higher potency than
saquinavir. The concentrations that inhibited R123 efflux by 50%
(IC50) were for saquinavir 9.39 ± 2.81 μM in UKF-NB-3
rVCR10 cells
and 2.45 ± 0.33 μM in UKF-NB-3MDR1 cells. The IC50 values for
saq-NO were 0.70 ± 0.14 μM in UKF-NB-3rVCR10 cells and
0.053 ± 0.021 μM in UKF-NB-3MDR1 cells.
To examine whether saq-NO may be a P-gp substrate, two experi-
ments were performed. Washout kinetics were determined, that is,
UKF-NB-3rVCR10 and UKF-NB-3MDR1 cells were incubated with
R123 in the presence or absence of saq-NO, saquinavir, or verapamil
(a known P-gp substrate). Then, cells were washed, and cellular fluo-
rescence was regularly measured by flow cytometry. Rapid decrease of
R123 fluorescence indicated that saq-NO and saquinavir are trans-
ported by P-gp (Figure 1B). Moreover, the influence of saquinavir
and saq-NO on P-gp–ATPase activity was measured. Saq-NO and
saq stimulated P-gp–ATPase activity, further confirming that saq-NO
and saquinavir are both P-gp substrates (Figure 1C ).
Influence of Saquinavir and Saq-NO on MRP1 Function
Saquinavir was shown to interfere withMRP1-mediated drug efflux
as a substrate [17,18]. In concordance, saquinavir enhanced sensitivity
of MRP1-expressing PC-3rVCR20 to the MRP1 substrate vincristine
(Table 4). Moreover, saquinavir increased accumulation of the fluo-
rescent dye 5-CFDA known to be a MRP1 substrate (Figure 2A).
Washout kinetics revealed a rapid decline of 5-CFDA fluorescence
in the presence of saquinavir (Figure 2B), and determination of
MRP1-ATPase activity showed that saquinavir stimulated MRP1 ac-
tivity (Figure 2C ) confirming that saquinavir is a MRP1 substrate. In
comparison to saquinavir, Saq-NO induced enhanced sensitization of
PC-3rVCR20 cells to vincristine (Table 4) and increased 5-CFDA ac-
cumulation in PC-3rVCR20 cells (Figure 2A). Washout kinetics
(Figure 2B) and measurement of MRP1-ATPase activity (Figure 2C )
demonstrated that Saq-NO is like saquinavir a MRP1 substrate.
Table 2. Sensitization of Cancer Cells to Structurally Different Anticancer Drugs Known to Be P-gp Substrates by Saq or Saq-NO Concentrations That Did Not Affect Cancer Cell Viability.
Cell Line (P-gp Status*) Anticancer Drug IC50
† (ng/ml)
Anticancer Drug
Saq (μM) IC50 (ng/ml) Anticancer Drug
in the Presence of Saq
(Fold Sensitization‡)
Saq-NO (μM) IC50 (ng/ml) Anticancer Drug
in the Presence of Saq-NO
(Fold Sensitization§)
UKF-NB-3 (−) Vincristine 0.20 ± 0.08 10 0.14 ± 0.02 (1.4) 5 0.10 ± 0.04 (2.0)
Actinomycin D 0.19 ± 0.07 10 0.18 ± 0.06 (1.1) 5 0.16 ± 0.05 (1.2)
Paclitaxel 1.12 ± 0.35 10 0.79 ± 0.15 (1.4) 5 0.88 ± 0.20 (1.3)
UKF-NB-3rVCR10 (+) Vincristine 40.29 ± 5.07 10 3.43 ± 0.93¶ (11.8) 5 0.31 ± 0.04¶,# (130.0)
Actinomycin D 6.58 ± 1.43 10 3.18 ± 1.15¶ (2.1) 5 0.22 ± 0.02¶,# (29.9)
Paclitaxel 40.86 ± 7.48 10 12.26 ± 2.23¶ (3.3) 5 3.05 ± 0.34¶,# (13.4)
Rh30 (−) Vincristine 0.56 ± 0.15 10 0.32 ± 0.07 (1.8) 2.5 0.39 ± 0.13 (1.4)
Actinomycin D 0.32 ± 0.10 10 0.28 ± 0.03 (1.1) 2.5 0.23 ± 0.07 (1.4)
Paclitaxel 4.48 ± 0.51 10 3.62 ± 0.65 (1.2) 2.5 3.73 ± 0.64 (1.2)
Rh30rVCR10 (+) Vincristine 37.21 ± 6.89 10 17.36 ± 3.41¶ (2.1) 5 0.21 ± 0.09¶,# (177.2)
Actinomycin D 12.85 ± 2.75 10 4.81 ± 1.39¶ (2.7) 5 1.49 ± 0.17¶,# (8.6)
Paclitaxel 90.74 ± 10.91 10 36.93 ± 7.18¶ (2.5) 5 6.77 ± 1.19¶,# (13.4)
Values are mean ± SD from three independent experiments.
*+ = high P-gp expression, − = low P-gp expression.
†Concentration that decreases cell viability by 50%.
‡IC50 anticancer drug/IC50 anticancer drug + saq.
§IC50 anticancer drug/IC50 anticancer drug + saq-NO.
¶P < .05 relative to anticancer drug alone.
#P < .05 relative to anticancer drug + saq.
Table 3. Sensitization of Stably P-gp–expressing MDR1-Transduced Cells (UKF-NB-3MDR1) to
Vincristine by Saq, Saq-NO, or Verapamil.
IC50* Vincristine (ng/ml) Fold Sensitization
†
Vincristine 13.17 ± 1.35
Vincristine + verapamil 10 μM 0.07 ± 0.004‡ 188.1
Vincristine + saq 10 μM 3.21 ± 0.71‡ 4.10
Vincristine + saq 5 μM 6.66 ± 1.72‡ 2.0
Vincristine + saq 2.5 μM 9.41 ± 2.22 1.4
Vincristine + saq-NO 10 μM 0.11 ± 0.01‡,§ 119.7
Vincristine + saq-NO 5 μM 0.85 ± 0.15‡,§ 15.5
Vincristine + saq-NO 2.5 μM 3.35 ± 0.93‡,§ 3.9
Values are mean ± SD from three independent experiments.
*Concentration that decreases cell viability by 50%.
†IC50 vincristine/IC50 vincristine + saq, saq-NO, or verapamil.
‡P < .05 relative to vincristine alone.
§P < .05 relative to vincristine + corresponding saq concentration.
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Influence of Saquinavir and Saq-NO on BCRP1 Function
Saquinavir was shown to be an inhibitor of BCRP1 but not a sub-
strate [20,21]. To investigate the influence of saquinavir and saq-NO
on BCRP1 function, UKF-NB-3 cells were transduced with LeGO
vectors [27] containing cDNA coding for BCRP1 to induce overex-
pression of BCRP1 (UKF-NB-3BCRP1; FigureW3). UKF-NB-3BCRP1
cells and the cell line resulting from transduction of UKF-NB-3 with
empty control vector LeGO-iG2 (UKF-NB-3LeGO-iG2; Figure W3)
showed similar sensitivity to saquinavir and saq-NO as UKF-NB-3
(Table 1).
Investigations in UKF-NB-3BCRP1 cells revealed that saquinavir
and saq-NO sensitized BCRP1-expressing cells to the BCRP1 sub-
strate mitoxantron in a similar manner (Table 5). Compared with
the BCRP1 inhibitor WK-X-34 [28] as well as the effects of saq-NO
Figure 1. Influence of saquinavir and saq-NO on P-gp activity. (A) Flow cytometric analysis of R123 accumulation in the P-gp–expressing
cell lines UKF-NB-3rVCR10 and UKF-NB-3MDR1. Cells were incubated with 1 μMR123. Verapamil 10 μM (vpl) was used as a positive control.
Saquinavir (saq) and saq-NO were tested at concentrations of 20, 10, and 5 μM, respectively. *P < .05 compared with R123. (B) Flow
cytometric analysis of washout kinetics for R123 in UKF-NB-3rVCR10 or UKF-NB-3MDR1 cells. Cells were incubated with 1 μM R123 for
1 hour, together with 10 μM verapamil (positive control), 10 μM saquinavir, or 10 μM saquinavir-NO. R123 specific fluorescence was
measured at FL1 channel after different time points (t0, t5, t15, t30, t60, and t120 minutes): (–•–) 1 μM R123, (–○–) 10 μM verapamil,
(–▾–) 10 μM saquinavir, (–▵–) 10 μM saq-NO. (C) P-gp–ATPase activity after incubation with 10 μM verapamil (vpl; positive control),
10 μM saquinavir (saq), or 10 μM saq-NO. *P < .05 compared with untreated control (ctrl). All data represent mean ± SD from three
independent experiments.
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on P-gp, effects were moderate. Therefore, effects of saq-NO on
BCRP1 are not superior to those exerted by saquinavir.
Discussion
HIV protease inhibitors including saquinavir exert anticancer activities
[1]. Recently, saq-NO, a nitric oxide–modified derivative of saquinavir
was synthesized, exerting stronger antitumoral effects but lower toxic
adverse effects [22]. Here, we compared the effects of saquinavir and
saq-NO on human cancer cells in dependence of cellular p53 status,
P-gp expression, MRP1 expression, and BCRP1 expression.
The anticancer effects of saq-NO were paralleled by activation of
p53 [22], and p53 activation had been documented to be involved
in the anticancer activity of the HIV protease inhibitor nelfinavir
[31]. However, HIV protease inhibitors including saquinavir were
found to also target cells with nonfunctional p53 [1,5]. In our ex-
periments, saq-NO and saquinavir exerted similar toxic effects against
p53 wild-type, p53-mutated, and p53-deleted cancer cells, with
saq-NO being the approximately three-fold more effective substance.
In addition, knock down of the p53 gene in the p53 wild-type UKF-
NB-3 cell line using a lentiviral vector expressing shRNA directed
against p53 did not influence UKF-NB-3 cell sensitivity to saq-NO
or saquinavir. Therefore, the anticancer activity of saq-NO includes
cancer cells with p53 mutations or deletions. These findings are im-
portant because p53 is the gene most frequently found mutated in
cancer cells and that loss of p53 function contributes to cancer cell
chemoresistance [32].
Also, the expression of the ABC transporters P-gp, MRP1, or
BCRP1 did not affect cancer cell sensitivity to saquinavir or saq-NO.
Because the expression of these transporters has been associated with
cancer cell multidrug resistance [11–14], this finding favors the use of
saq-NO for the treatment of drug-resistant cancer cells. Moreover,
ABC transporters including P-gp, MRP1, and BCRP1 have been sug-
gested to be expressed on so-called “cancer stem cells” or “tumor-
initiating cells” that are regarded to be critical targets in anticancer
therapy at least in some cancer entities [33–35].
In addition to the direct anticancer effects of saq-NO in ABC
transporter–expressing cancer cells, we investigated the effects of
saq-NO on P-gp–, MRP1-, and BCRP1-mediated drug efflux. Sub-
stances that interfere with ABC transporter function can sensitize
ABC transporter–expressing cancer cells to cytotoxic drugs. HIV pro-
tease inhibitors including saquinavir have already been shown to affect
ABC transporter–mediated drug efflux [15–21]. Saq-NO interfered
substantially stronger with the P-gp–mediated drug efflux than sa-
quinavir. As indicated by washout kinetics and P-gp–ATPase activ-
ity, saq-NO is like saquinavir, a P-gp substrate that competes with
other substrates for binding to P-gp. Saq-NO also exerted stronger
effects on MRP1 than saquinavir, and it is like saquinavir, an MRP1
Table 4. Sensitization of MRP1-Expressing PC-3rVCR20 Cells to Vincristine by Saq, Saq-NO, or
MK571 (MRP1 Inhibitor).
IC50* Vincristine Fold Sensitization
†
Vincristine 33.10 ± 4.07
Vincristine + MK571 10 μM 12.54 ± 1.88‡ 3.7
Vincristine + saq 5 μM 4.28 ± 0.61‡ 7.7
Vincristine + saq 2.5 μM 8.76 ± 1.19‡ 3.8
Vincristine + saq-NO 5 μM 2.73 ± 0.42‡,§ 12.1
Vincristine + saq-NO 2.5 μM 4.51 ± 0.73‡,§ 7.3
Values are mean ± SD from three independent experiments.
*Concentration that decreases cell viability by 50%.
†IC50 vincristine/IC50 vincristine + saq, saq-NO, or MK571.
‡P < .05 relative to vincristine alone.
§P < .05 relative to vincristine + corresponding saq concentration.
Figure 2. Influence of saquinavir and saq-NO on MRP1 activity.
(A) Flow cytometric analysis of 5-CFDA accumulation in the MRP1-
expressing cell line PC-3rVCR20. Cells were incubated with 4 μM
5-CFDA. MK571 10 μM was used as a positive control. Saquinavir
(saq) and saq-NO were tested at concentrations of 10 μM. *P< .05
compared with 5-CFDA. (B) Flow cytometric analysis of washout
kinetics for 5-CFDA in PC-3rVCR20 cells. Cells were incubated with
4 μM 5-CFDA for 1 hour, together with 10 μMMK571 as a positive
control, 10 μM saquinavir (saq), or 10 μM saquinavir-NO (saq-NO).
5-CFDA–specific fluorescence was measured at FL1 channel after
different time points (t0, t5, t15, t30, t60, and t120 minutes): (–•–) 4 μM
5-CFDA, (–○–) 10 μM MK571, (–▾–) 10 μM saquinavir, (–▵–) 10 μM
saquinavir-NO. (C) MRP1-ATPase activity after incubation with
10 μM NEM-GS (N -ethylmaleimide glutathione; positive control),
10 μM saquinavir (saq), or 10 μM saquinavir-NO (saq-NO). *P <
.05 compared with untreated control (ctrl). All data represent
mean ± SD from three independent experiments.
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substrate. In contrast, saq-NO and saquinavir exerted similar effects
on BCRP1 function.
ABC transporter inhibitors, especially P-gp inhibitors, have been
intensively investigated as anticancer drugs [11–14,36,37]. The first-
generation inhibitors including verapamil and cyclosporine A were
drugs established for other indications than cancer that had been iden-
tified to be P-gp substrates. Their use was limited by toxic (off-target)
adverse effects [11–14,36,37]. Later generations were more specific
and acted as noncompetitive ABC transporter inhibitors. However,
although some clinical phase 1 and 2 trials with ABC transporter
inhibitors seemed to be encouraging, successful phase 3 trials are miss-
ing [11–14,36,37]. Therefore, the development of ABC transporter
inhibitors for anticancer therapies is currently regarded with skepti-
cism [37]. One reason for the clinical failure of ABC transporters
may be that chemoresistant cancer (stem) cells express multiple
ABC transporters and inhibition of one is not sufficient [38]. The
use of the broad-spectrum ABC transporter inhibitor cyclosporine
A had initially shown beneficial effects in clinical trials in patients
with acute myeloid leukemia [39,40], although the use of this drug
in cancer is limited by its immunosuppressive effects and by numer-
ous further severe adverse effects including nephrotoxicity [38]. There-
fore, the ability to interfere with different ABC transporters may
be an advantage for a potential anticancer drug. More importantly,
data about the effects of potential anticancer agents are of high
relevance 1) for pharmacokinetic considerations because ABC trans-
porters are key players in the transport of substances through phys-
iological barriers [12] and 2) for interpretation of substance effects
in combination with other anticancer agents that are ABC trans-
porter substrates.
In conclusion, we show that the saquinavir derivative saq-NO exerts
stronger antitumoral effects than saquinavir. Saq-NO is equally effec-
tive against multidrug-resistant cancer cells characterized by P-gp ex-
pression,MRP1 expression, BCRP1 expression, and/or nonfunctional
p53. Moreover, saq-NO shows increased inhibition of P-gp– or
MRP1-mediated drug efflux in comparison to saquinavir and similar
inhibitory activity on BCRP1. In this light, further investigation of
saquinavir and saq-NO as potential anticancer drugs seems worth-
while, especially in combination with chemotherapeutic agents against
multidrug-resistant tumor cells. Clinical experience with saquinavir is
very strong, its toxicity profile is relatively mild compared with cyclo-
sporine A or anticancer chemotherapeutics [42], and the first experi-
mental results suggest that saq-NOmay cause less toxic adverse effects
than saquinavir [22].
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Figure W1. (A) Scheme of the lentiviral vectors, as integrated proviruses, that have been used in this study (not drawn to scale).Ψ indicates
packaging signal; cPPT, central polypurine tract; H1/TO, RNA-polymerase III promoter; mCherry, a red fluorescent protein; RRE, rev-
responsive element; SFFV, spleen focus–forming virus enhancer/promoter; shRNA-p53, short hairpin RNA against human p53; shRNA-
scr, short hairpin RNA with no target (scrambled); SIN-LTR, self-inactivating long-terminal repeat; wPRE, Woodchuck hepatitis virus
posttranscriptional regulatory element. (B) UKF-NB-3, UKF-NB-3 transduced with LeGO-C-scr-shRNA (UKF-NB-3scr-shRNA, and UKF-NB-3
transduced with LeGO-C-p53-shRNA (UKF-NB-3p53-shRNA) cells were photographed by inverse light microscopy (a, c, and e) and by fluo-
rescence microscopy (b, d, and f), using an IX71 fluorescence microscope (Olympus). Fluorescence dye mCherry was detected at 587/
610 nm (excitation/emission). The nontransduced control cell line UKF-NB-3 showed no fluorescence (b). In contrast, UKF-NB-3scr-shRNA
and UKF-NB-3p53-shRNA cells displayed high fluorescence due to successful transduction with shRNAs (d, f). (C) Western blot was carried
out with UKF-NB-3 (a), UKF-NB-3p53-shRNA (b), and UKF-NB-3scr-shRNA (c) cells, detecting p53 (Alexis Biochemicals through AXXORA
Deutschland) and β-actin as control (Sigma). The cell lines UKF-NB-3 and UKF-NB-3scr-shRNA showed clear expression of p53 (a and c).
In contrast, UKF-NB-3p53-shRNA cells displayed significant decreased p53-expression (b) due to successful transductionwith shRNA against
p53. Densitometric analysis revealed at least 70% down-regulation of p53. (D) Concentrations of the MDM2 inhibitor nutlin-3a that non-
genotoxically activates p53, its enantiomer nutlin-3b that shows 150-fold lower MDM2-inhibitory activity, and of the cytotoxic drugs
vincristine and doxorubicin that reduce cell viability by 50% (IC50) as indicated by MTT assay. Values are mean ± SD from three indepen-
dent experiments. *P < .05 relative to nontransfected cells.
Materials and Methods
Cloning of Lentiviral Vectors
Standard molecular cloning techniques were used to generate viral
vectors based on Lentiviral Gene Ontology (LeGO) vectors [1] (also
http://www.LentiGO-Vectors.de). Maps and sequence data of the vec-
tors are available on request. The 60-bp shRNA against human p53 or
the 60-bp scrambled shRNA was cloned into LeGO-C using XbaI
and XhoI. The internal promoter H1/TO transcribes the shRNA
against p53 or the scrambled shRNA, respectively. The internal SFFV
promoter drives the expression of the red fluorescent protein mCherry
as a marker gene.
Generation of Viral Particles
Cell-free viral supernatants were generated by transient trans-
fection of 293T packaging cells as described [2], using the third-
generation packaging plasmids pMDLg/pRRE and pRSV-Rev [3]
together with phCMV-VSV-G [2]. Supernatants containing pseudo-
typed vector particles were titrated on 293T target cells. Gene transfer
rates were analyzed 2 days after transduction by fluorescence-activated
cell sorting (FACS). Titers of 1.5 × 107 (LeGO-C-p53-shRNA) and
2 × 107 (LeGO-C-scr-shRNA) VSV-G pseudotyped virus particles per
milliliter of unconcentrated supernatants were obtained.
Cell Culture and Lentiviral Gene Transfer
All cells were cultured in their respective growth medium sup-
plemented with penicillin/streptomycin. For transduction of UKF-
NB-3 target cells, 5 × 104 cells in 500 μl of medium were plated per
well in a 24-well plate. The next day, 250 μl of viral supernatant per
well was added in the presence of 8 μg/ml polybrene, and the plate was
centrifuged at 1000g for 1 hour at room temperature. After another
3 hours in the cell culture incubator, medium was replaced.
Fluorescence Microscopy
Pictures were taken using an IX71 fluorescence microscope
(Olympus, Hamburg, Germany). Fluorescence dye mCherry was
detected at 587 nm emission/610 nm excitation.
Western Blot
Cells were lysed in Triton X sample buffer and separated by SDS-
PAGE, as described before [4]. Proteins were detected using spe-
cific antibodies against β-actin (Sigma, Munich, Germany) or p53
(Alexis Biochemicals through AXXORA Deutschland, Lörrach,
Germany) and were visualized by enhanced chemiluminescence using
a commercially available kit (Amersham through GE Healthcare,
Munich, Germany).
MTT Assay
Cell viability was tested by the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) dye reduction assay after
96 hours of incubation modified as described before [5].
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Figure W1. (continued).
Figure W2. (A) Scheme of the lentiviral vectors, as integrated proviruses, that have been used in this study (not drawn to scale).Ψ indicates
packaging signal; Cerulean, a blue variant of the enhanced green fluorescent protein; cPPT, central polypurine tract; hMDR1, human mul-
tiple drug resistance gene cDNA; IRES, internal ribosome entry site of the EMCV; RRE, rev-responsive element; SFFV, spleen focus–forming
virus enhancer/promoter; SIN-LTR, self-inactivating long terminal repeat; wPRE, Woodchuck hepatitis virus posttranscriptional regulatory
element. (B) UKF-NB-3, UKF-NB-3 transduced with LeGO-Cer2 (UKF-NB-3LeGO-Cer2), and UKF-NB-3 transduced with LeGO-iCer2-MDR1
(UKF-NB-3MDR1) cells were photographed by inverse light microscopy (a, c, e) and by fluorescence microscopy (b, d, f), using an IX71 fluo-
rescencemicroscope (Olympus). Fluorescence dye Cerulean was detected at 433/475 nm (excitation/emission). The nontransduced control
cell line UKF-NB-3 showed no fluorescence (b). In contrast, UKF-NB-3LeGO-Cer2 and UKF-NB-3MDR1 cells displayed high fluorescence due to
successful transduction with LeGO-vectors (d, f). (C) Flow cytometric analysis of MDR1 expression. (a) Flow cytometric histograms of the
cell lines UKF-NB-3 (negative control), UKF-NB-3rVCR10 (positive control), UKF-NB-3 transduced with 100 μl of control vector LeGO-Cer2
(UKF-NB-3LeGO-Cer2) and UKF-NB-3 transduced with 100 μl of human MDR1-expressing vector LeGO-iCer2b-MDR1 (UKF-NB-3MDR1). (b)
Quantitative analysis of flow cytometry data. *P < .05 relative to nontransduced UKF-NB-3 cells. (D) Flow cytometric analysis of MDR1
expression in the cell lines UKF-NB-3, UKF-NB-3rVCR10, UKF-NB-3LeGO-Cer2, and UKF-NB-3MDR1 untreated (black bars), treated with 10 μM
saquinavir for 5 days (gray bars) or treated with 10 μM saquinavir-NO for 5 days (dark gray bars). Incubation with saquinavir or saquinavir-NO
had no influence on MDR1 expression. (E) Concentrations that decrease cell viability by 50% (IC50) for the MDR1 substrate vincristine in-
vestigated by MTT assay (values are means ± SD). MDR1-expressing cell lines UKF-NB-3MDR1 and UKF-NB-3rVCR10 showed higher IC50
values for vincristine compared with MDR1-negative cell lines UKF-NB-3 and UKF-NB-3LeGO-Cer2. 1P < .05 relative to UKF-NB-3. 2P < .05
relative to UKF-NB-3rVCR10. 3P < .05 relative to UKF-NB-3MDR1.
Figure W2. (continued).
Materials and Methods
Cloning of Lentiviral Vectors
Standard molecular cloning techniques were used to generate viral
vectors based on Lentiviral Gene Ontology (LeGO) vectors [1] (also
http://www.LentiGO-Vectors.de). Maps and sequence data of the vec-
tors are available on request. In the first step, the multiple cloning site of
the lentiviral vector LeGO-Cer2 was inverted, resulting in LeGO-
iCer2b. Then, the 3842-bp cDNA of the human MDR1 gene was
taken out of the γ-retroviral vector SF91m3.IRES.GFP [2,3] (kindly
provided by A. Schambach and C. Baum, MH Hannover, Germany)
and cloned into LeGO-iCer2b using BamHI and NotI. The internal
SFFV promoter of this vector transcribes a bicistronic messenger
RNA (mRNA) with an internal ribosome entry site (IRES) of the
encephalomyocarditis virus (EMCV), expressing the hMDR1 together
with the blue fluorescent protein Cerulean as a marker. The vector
LeGO-Cer2 only expressing Cerulean served as a control.
Generation of Viral Particles
Cell-free viral supernatants were generated by transient transfection
of 293T packaging cells as described [4], using the third-generation
packaging plasmids pMDLg/pRRE and pRSV-Rev [5] together with
phCMV-VSV-G [4]. Supernatants containing pseudotyped vector
particles were titrated on 293T target cells. Gene transfer rates were
analyzed 2 days after transduction by fluorescence-activated cell sort-
ing (FACS). Titers of 4 × 106 (LeGO-iCer2b-MDR1) and 8 × 106
(LeGO-Cer2) VSV-G pseudotyped virus particles per milliliter of
unconcentrated supernatants were obtained.
Cell Culture and Lentiviral Gene Transfer
All cells were cultured in their respective growth medium sup-
plemented with penicillin/streptomycin. For transduction of UKF-
NB-3 target cells, 5 × 104 cells in 500 μl of medium were plated per
well in a 24-well plate. The next day, 250 μl of viral supernatant per
well was added in the presence of 8 μg/ml polybrene, and the plate was
centrifuged at 1000g for 1 hour at room temperature. After another
3 hours in the cell culture incubator, medium was replaced.
Fluorescence Microscopy
Pictures were taken using an IX71 fluorescence microscope
(Olympus, Hamburg, Germany). Fluorescence dye Cerulean was
detected at 433 nm emission/475 nm excitation.
Flow Cytometric Analysis
Flow cytometric data were acquired using the cytometer FACS-
Calibur (488 nm laser; Becton Dickinson, Heidelberg, Germany).
Staining of hMDR1-positive cells was carried out using an anti–P-
glycoprotein antibody (Alexis Biochemicals through AXXORA
Deutschland, Lörrach, Germany), followed by staining with a second-
ary PE-labeled antibody (R&D, Wiesbaden, Germany).
MTT Assay
Cell viability was tested by the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) dye reduction assay after
96 hours of incubation modified as described before [6].
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Figure W3. (A) Scheme of the lentiviral vectors, as integrated proviruses, that have been used in this study (not drawn to scale).Ψ indicates
packaging signal; cPPT, central polypurine tract; eGFP, enhanced green fluorescent protein; hBCRP1, human breast cancer resistance pro-
tein 1 gene cDNA; IRES, internal ribosomeentry site of the EMCV; RRE, rev-responsive element; SFFV, spleen focus–forming virus enhancer/
promoter; SIN-LTR, self-inactivating long terminal repeat; wPRE, Woodchuck hepatitis virus posttranscriptional regulatory element. (B) UKF-
NB-3 cells, UKF-NB-3 cells transduced with LeGO-iG2 (UKF-NB-3LeGO-iG2), and UKF-NB-3 cells transduced with LeGO-iG2-BCRP1 (UKF-
NB-3BCRP1) were photographed by inverse light microscopy (a, c, e) and by fluorescence microscopy (b, d, f) using an IX71 fluorescence
microscope (Olympus). Fluorescence dye eGFP was detected at 484/507 nm (excitation/emission). The nontransduced control cell line
UKF-NB-3 showed no fluorescence (b). In contrast, UKF-NB-3LeGO-iG2 and UKF-NB-3BCRP1 cells displayed high fluorescence due to successful
transduction with LeGO vectors (d, f). (C) Flow cytometric analysis of BCRP1 expression. (a) Flow cytometric histograms of the cell lines
UKF-NB-3 (negative control), UKF-NB-3 transduced with 100 μl of control vector LeGO-iG2 (UKF-NB-3LeGO-iG2) and UKF-NB-3 transducedwith
100 μl of human BCRP1-expressing vector LeGO-iG2-BCRP1 (UKF-NB-3BCRP1). (b) Quantitative analysis of flow cytometry data. *P < .05
relative to nontransduced UKF-NB-3 cells. (D) Flow cytometric analysis of BCRP1 expression in the cell lines UKF-NB-3, UKF-NB-3LeGO-iG2,
and UKF-NB-3BCRP1 untreated (black bars), treated with 10 μMsaquinavir for 5 days (gray bars) or treated with 10 μMsaq-NO for 5 days (dark
gray bars). Incubation with saquinavir or saquinavir-NO had no influence on BCRP1 expression. (E) Concentrations that decrease cell viability
by 50% (IC50) for the BCRP1 substrate mitoxantrone, determined by MTT assay (values are means ± SD) in the absence or presence of
the BCRP1 inhibitor WK-X-34. BCRP1-expressing cell line UKF-NB-3BCRP1 showed higher IC50-values for mitoxantrone compared with
BCRP1-negative cell lines UKF-NB-3 and UKF-NB-3LeGO-iG2. 1P < .05 relative to UKF-NB-3. 2P < .05 relative to UKF-NB-3BCRP1.
Figure W3. (continued).
Materials and Methods of Viral Transduction
Cloning of Lentiviral Vectors
Standard molecular cloning techniques were used to generate viral
vectors based on Lentiviral Gene Ontology (LeGO) vectors [1] (also
http://www.LentiGO-Vectors.de). Maps and sequence data of the
vectors are available on request. The lentiviral vector LeGO-iG2 was
used as backbone vector. Then, the 1968-bp cDNA of the human
BCRP1 gene was cloned into LeGO-iG2 using BamHI and NotI.
The internal SFFV promoter of this vector transcribes a bicistronic
mRNAwith an IRES of the EMCV, expressing the hBCRP1 together
with the enhanced green fluorescent protein (eGFP) as a marker. The
vector LeGO-iG2 only expressing GFP served as a control.
Generation of Viral Particles
Cell-free viral supernatants were generated by transient transfection
of 293T packaging cells as described [2], using the third-generation
packaging plasmids pMDLg/pRRE and pRSV-Rev [3] together with
phCMV-VSV-G [2]. Supernatants containing pseudotyped vector
particles were titrated on 293T target cells. Gene transfer rates were
analyzed 2 days after transduction by fluorescence-activated cell sort-
ing (FACS). Titers of 2.4 × 106 (LeGO-iG2-BCRP1) and 5 × 106
(LeGO-iG2) VSV-G pseudotyped virus particles per milliliter of
unconcentrated supernatants were obtained.
Cell Culture and Lentiviral Gene Transfer
All cells were cultured in their respective growth medium sup-
plemented with penicillin/streptomycin. For transduction of UKF-
NB-3 target cells, 5 × 104 cells in 500 μl of medium were plated per
well in a 24-well plate. The next day, 250 μl of viral supernatant per
well was added in the presence of 8 μg/ml polybrene, and the plate was
centrifuged at 1000g for 1 hour at room temperature. After another
3 hours in the cell culture incubator, medium was replaced.
Fluorescence Microscopy
Pictures were taken using an IX71 fluorescence microscope
(Olympus, Hamburg, Germany). Fluorescence dye eGFP was de-
tected at 484 nm emission/507 nm excitation.
FACS Analysis
FACS data were acquired using the cytometer FACSCalibur (488 nm
laser; Becton Dickinson, Heidelberg, Germany). Staining of hBCRP1-
positive cells was carried out using an anti-hBCRP1 antibody (Kamiya
Biomedical Company, Seattle, WA) followed by staining with a sec-
ondary PE-labeled antibody (R&D, Wiesbaden, Germany).
MTT Assay
Cell viability was tested by the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) dye reduction assay after
96 hours of incubation modified as described before [4].
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